Note: Ingredients listed on restricted chemical lists
EC/CAS
1310-73-2
Name of the chemical
sodium hydroxide
Concentration
N/A
EC/CAS
7647-01-0
Name of the chemical
Hydrochloric acid
Concentration
N/A
EC/CAS
7732-18-5
Name of the chemical
Water, distilled, conductivity or of similar purity H2O
Concentration
80-85
General Information
Version
6.0
Revision date
2025-07-26
Product name
Ketorolac Tromethamine Injection, USP
Chemical name
(±)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)
1.2.1 Relevant identified uses
Pharmaceutical
Icons in SDS
Company Information
company name
Sagent Pharmaceuticals
GHS Information
Signal word
DANGER
Hazard Codes
Hazard statements (CLP)
H360D
Hazard statements
Code
Statements
H360D
May damage the unborn child
Section 2
SECTION 2: Hazards identification
2.1 Classification of the substance or mixture
N/A
Signal word
DANGER Hazard statement(s), May damage the unborn child. Symbol(s), and/or May cause damage to gastrointestinal system through
Precautionary statements
prolonged or repeated exposure. (c) Description of Hazards Short Term: Accidental ingestion may cause effects similar to those seen in clinical use. Individuals sensitive to this chemical or other materials in its chemical class may develop allergic reactions. Known Clinical Effects: Other nonsteroidal anti- inflammatory drugs (NSAIDs) are known to impact delivery, late fetal development, and lactation. Ingestion of this material may cause effects similar to those seen in clinical use including serious gastrointestinal toxicity such as bleeding, ulceration, and perforation and kidney toxicity. Clinical use of this drug has caused headache, dizziness, blurred vision, ringing of the ears, skin rash, itching, swelling, liver effects. (d) Unknown Acute Toxicity: N/A
